 SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 GLOBE NEWSWIRE -- Assembly Biosciences, Inc. Nasdaq: ASMB, a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus HBV, today announced the promotions of Jason Okazaki to chief operating officer and Michael Samar to chief financial officer. Mr. Okazaki joined Assembly Bio in 2020 as chief legal and business officer responsible for leading and executing strategic collaborations and transactions. Since joining Assembly Bio in 2017, Mr. Samar has led the companys financial and business operations, serving most recently as senior vice president of finance and business operations. 